Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Void

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    135 result(s) found for: Void. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2011-006120-20 Sponsor Protocol Number: 31-06-2011 Start Date*: 2012-03-15
    Sponsor Name:University Medical Centre Ljubljana
    Full Title: Efficacy and safety of selective vitamin D receptor activation with paricalcitol for reduction of proteinuria in kidney transplant recipients: a randomized controlled trial
    Medical condition: Proteinuria in kidney transplant recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004176-18 Sponsor Protocol Number: CHK01-02 Start Date*: 2021-06-21
    Sponsor Name:Chinook Therapeutics U.S., Inc.
    Full Title: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
    Medical condition: Proteinuric glomerular diseases, including: Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g) Focal segmental glomerulosclerosis (FSGS) Alport Syndrome Diabetes kidney disease (DKD) (...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004929-23 Sponsor Protocol Number: 2020/1002 Start Date*: 2021-04-14
    Sponsor Name:University Medical Center Groningen
    Full Title: Individual albuminuria lowering response to dapagliflozin in a decentralized clinical trial in patients with type 2 diabetes mellitus and elevated albuminuria
    Medical condition: Patients with type 2 diabetes and albuminuria >20 mg/g (2.26 mg/mmol)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002546-49 Sponsor Protocol Number: SCP-01-001 Start Date*: 2014-10-03
    Sponsor Name:scPharmaceuticals Inc
    Full Title: A single center, randomized, open-label, cross-over exploratory study to evaluate the pharmacodynamic and pharmacokinetic response to a subcutaneous administration or oral administration of furosem...
    Medical condition: Fluid overload in heart failure
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000950-39 Sponsor Protocol Number: BAY94-8862/17530 Start Date*: 2015-09-09
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular mor...
    Medical condition: Type II Diabetes Mellitus and Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) HU (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) ES (Completed) FI (Completed) PT (Completed) BE (Completed) BG (Completed) NL (Completed) LT (Completed) PL (Completed) FR (Completed) GR (Completed) RO (Completed) IE (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003940-35 Sponsor Protocol Number: KF6010-02 Start Date*: 2017-05-22
    Sponsor Name:Grünenthal GmbH
    Full Title: Exploratory, randomized, double-blind, placebo-controlled evaluation of efficacy, tolerability, and safety of intravesical instillation of GRT6010 compared to placebo in subjects with bladder pain ...
    Medical condition: Bladder pain syndrome.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004857 10071166 Bladder pain syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001434-19 Sponsor Protocol Number: 1378.5 Start Date*: 2021-12-24
    Sponsor Name:Boehringer Ingelheim SComm
    Full Title: Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagl...
    Medical condition: chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) IT (Completed) NO (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Ongoing) DK (Prematurely Ended) BG (Completed) GR (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000990-11 Sponsor Protocol Number: BAY94-8862/16244 Start Date*: 2015-09-09
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on t...
    Medical condition: Type II Diabetes Mellitus and Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) GB (Completed) AT (Completed) CZ (Completed) ES (Completed) FI (Completed) PT (Completed) BE (Completed) NL (Completed) FR (Completed) DE (Completed) LT (Completed) PL (Completed) GR (Completed) RO (Completed) IE (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002055-32 Sponsor Protocol Number: PSD506-OAB-004 Start Date*: 2006-10-09
    Sponsor Name:Plethora Solutions Limited
    Full Title: A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruct...
    Medical condition: This study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in li...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055026 Prostatic obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) IE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001021-28 Sponsor Protocol Number: 1208.22 Start Date*: 2005-09-05
    Sponsor Name:Boehringer Ingelheim GmbH
    Full Title: .A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 1...
    Medical condition: stress urinary incontinence and stress predominant mixed urinary incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003471-30 Sponsor Protocol Number: D-FR-52120-222 Start Date*: 2016-09-26
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) PT (Completed) CZ (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004192-41 Sponsor Protocol Number: A0221109 Start Date*: 2020-09-03
    Sponsor Name:Pfizer
    Full Title: LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR ...
    Medical condition: Urinary Bladder, Neurogenic
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004388-34 Sponsor Protocol Number: 000088 Start Date*: 2013-03-06
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated with Desmopressin Orally Disintegrating Tablets as compared to Pl...
    Medical condition: Nocturia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000452-34 Sponsor Protocol Number: 3004 Start Date*: 2013-11-19
    Sponsor Name:Steno Diabetes Center
    Full Title: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria
    Medical condition: Patients with type 2 diabetes mellitus and normoalbuminuria
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) CZ (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004082-39 Sponsor Protocol Number: GOOD-IDES-01 Start Date*: 2017-01-23
    Sponsor Name:Linköping University
    Full Title: An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES
    Medical condition: Anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10063039 Anti-GBM antibody LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000891-27 Sponsor Protocol Number: CLNP023X2203 Start Date*: 2017-11-21
    Sponsor Name:Novartis Pharma AG
    Full Title: An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients
    Medical condition: Primary IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10029149 Nephropathies HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) CZ (Completed) HU (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001846-24 Sponsor Protocol Number: 1 Start Date*: 2016-06-29
    Sponsor Name:Antwerp University Hospital
    Full Title: Metabolism of Isotonic versus Hypotonic Maintenance Solutions in fasting healthy Adults (MIHMoSA), a Single-Blind Randomized Crossover Trial
    Medical condition: Healthy adult volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002820-20 Sponsor Protocol Number: OZBS62.14078 Start Date*: 2016-02-03
    Sponsor Name:Erasmus MC Dept. Urology
    Full Title: Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?
    Medical condition: Bladder dysfunction in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10069632 Bladder dysfunction PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022138-10 Sponsor Protocol Number: FI.LU.VA Start Date*: 2010-07-28
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PER...
    Medical condition: men with persistent irritative urinary symptoms
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038359 - Renal and urinary disorders 10005034 Bladder discomfort PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001680-40 Sponsor Protocol Number: 000015 Start Date*: 2016-05-10
    Sponsor Name:Vestfold Hospital
    Full Title: Pilot study to evaluate the effect of instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder using Electromotive Drug Application (EMDA) in women with overactive bladder.
    Medical condition: Overactive bladder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:33:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA